Books by Subject
- 3D cell-based biosensors in drug discovery programs — Dose finding by the continual reassessment method (100)
- Drug absorption studies — Methylxanthines (100)
- Microbial genomics and drug discovery — Radiopharmaceuticals (100)
- Raman and SERS investigations of pharmaceuticals — What your patients need to know about psychiatric medications (39)
PharmacologyAccess restricted to Stanford unless otherwise noted
- Microbial genomics and drug discovery 2003, CRCnetBASE
- Microdialysis in drug development 2013, SpringerIn vivo target site concentrations are probably the most important determinant of drug effects. Traditionally, linking drug concentrations to drug effects has been accomplished by modelling blood-derived data, mostly because a direct quantification of tissue concentrations has been beyond technical reach. Today, a direct measurement of target site concentrations is possible by employing microdialysis or complementary approaches such as imaging technologies. Microdialysis, initially conceived in the 1970s, has become a standard tool in drug development. This comprehensive overview of current microdialysis technology covers general and disease-specific aspects of microdialysis by international experts in the field. It provides useful information for colleagues in academia and industry who are interested PK-PD aspects of drug development.
- Modern anesthetics 2008, Springer
- Molecular chaperones in health and disease 2006, Springer
- "Preface Over the past few decades, molecular modeling (MM) has become an important tool in many academic institutions and industrial laboratories. While the role of MM in biological fields--especially in the design and development of novel drug molecules or formulations--is well established and acknowledged, its direct role in the design and development of performance chemicals and novel materials is still not well known. Questions such as, which new products have resulted from an MM-based approach? are still often asked. Although MM may be playing an important role in product development, quite often it becomes difficult to predict its direct impact because most of the time the problem being addressed involves a multidisciplinary approach. Further, the assumption that fundamental phenomena being modeled though MM will have a direct impact on the macroscopic and functional properties of a product make the situation more complicated. In most of the cases, MM actually works as an enabler toward novel product and material development (e.g., novel drug molecules in biological application) rather than directly coming up with new products and materials. This precisely is the reason that despite seeing value in MM tools, most engineers and practitioners are often focus on the question, how do I leverage these tools to design and develop novel materials or chemicals for the industry I am working with? Unfortunately, there is no simple answer to this question. Excellent books and very good research publications highlight the most intricate, fundamental, and theoretical details about MM techniques and tools"--Provided by publisher.
- Molecular pharmacognosy 2013, Springer"This book reviews the latest developments in pharmacognosy, introduces a series of new views and insights, presents the hotspots and focus of the field of study on molecular pharmacognosy, and predicts a new direction of study on the resource science of TCM. Furthermore, the book also provides an open communications platform for the development of molecular pharmacognosy."--Publisher.
- Molecular, clinical, and environmental toxicology. Volume 3, Environmental toxicology 2012, SpringerChemical Hazards in the Organisation / Chris Winder -- Toxicology of Water / Xiaowei Zhang, Steve Wiseman and John Giesy -- Perfluorinated Compounds / Christopher Lau -- Toxicologically Relevant Phthalates in Food / Oliver Kappenstein, Bärbel Vieth, Andreas Luch and Karla Pfaff -- Exposure to Polycyclic Aromatic Hydrocarbons: Bulky DNA Adducts and Cellular Responses / Frank Henkler, Kristin Stolpmann and Andreas Luch -- Heavy Metal Toxicity and the Environment / Paul B. Tchounwou, Clement G. Yedjou, Anita K. Patlolla and Dwayne J. Sutton -- Toxicology of Ambient Particulate Matter / Damiën van Berlo, Maja Hullmann and Roel P. F. Schins -- Nanomaterials: A Challenge for Toxicological Risk Assessment? / Andrea Haase, Jutta Tentschert and Andreas Luch -- Immunotoxicology and Its Application in Risk Assessment /; Andrew A. Rooney, Robert W. Luebke, MaryJane K. Selgrade and Dori R. Germolec.; Chemical Sensitization and Allergotoxicology / Rosette L. Van Den Heuvel, Nathalie Lambrechts, Sandra Verstraelen, Inge C. Nelissen and Greet E. R. Schoeters -- Male Reprotoxicity and Endocrine Disruption / Sarah Campion, Natasha Catlin, Nicholas Heger, Elizabeth V. McDonnell and Sara E. Pacheco, et al. -- Interspecies Uncertainty in Molecular Responses and Toxicity of Mixtures / Moiz M. Mumtaz and Hana R. Pohl -- Recent Trends in Statistical QSAR Modeling of Environmental Chemical Toxicity / Alexander Tropsha -- Chirality and Its Role in Environmental Toxicology / Imran Ali, Hassan Y. Aboul-Enein, Mohd Marsin Sanagi and Wan Aini Wan Ibrahim -- Genetic Variability in Molecular Responses to Chemical Exposure / Chirag J. Patel and Mark R. Cullen -- Biomarkers in Toxicology and Risk Assessment / Bruce A. Fowler -- A Personalized Life: Biomarker Monitoring from Cradle to Grave / Harald Jungnickel and Andreas Luch -- On the Role of Low-Dose Effects and Epigenetics in Toxicology / Lena Smirnova, Alexandra Sittka and Andreas Luch -- Hormesis: Improving Predictions in the Low-Dose Zone / E. J. Calabrese.
- Morphine and metastasis 2013, SpringerThis book would combine chapters written by the most qualified authors around the world whose research encompasses the effect of morphine or other opioids on tumor growth and metastasis. This includes clinicians involved in trials determining which type of post surgical pain management can minimize the risk of recurrence or metastasis, researchers working on animal models and studying the effect of morphine on tumors, and most importantly the mechanism for this effect, and lastly cell biologists. There is currently a lot of research going on trying to reconcile the pro- and anti-cancer aspects of opioids actions.
- Multifunctional pharmaceutical nanocarriers 2008, Springer
- Muscarinic receptors 2012, SpringerMuscarinic receptor pharmacology and signaling -- Overview of muscarinic receptor subtypes -- Structure-function studies of muscarinic acetylcholine receptors -- Polymorphisms in human muscarinic receptor subtype genes -- Muscarinic receptor trafficking -- Physiological role of G-protein coupled receptor phosphorylation -- Novel muscarinic receptor mutant mouse models -- Muscarinic receptors in the CNS -- Muscarinic receptor pharmacology and circuitry for the modulation of cognition -- Muscarinic agonists and antagonists in schizophrenia -- Muscarinic pain pharmacology: realizing the promise of novel anagesics by overcoming old challenges -- Muscarinic modulation of striatal function and circuitry -- Muscarinic receptors in brain stem and mesopontine cholinergic arousal functions -- Muscarinic receptors in autonomic effector organs -- Muscarinic receptor agonists and antagonists: effects on ocular function -- Muscarinic receptor agonists and antagonists: effects on cardiovascular function -- Muscarinic receptor antagonists: effects on pulmonary function -- Muscarinic agonists and antagonists: effects on gastrointestinal function -- Muscarinic agonists and antagonists: effets on the urinary bladder -- Muscarinic receptors and mediation of hormonal effects of acetylcholine -- Muscarinic receptor agonists and antagonists: effects on inflammation and immunity -- Muscarinic receptor agonists and antagonists: effects on keratinocyte functions -- Muscarinic receptor agonists and antagonists: effects on cancer -- Activation of muscarinic receptors by non-neuronal acetylcholine.
- Nanoneuroscience and nanoneuropharmacology 2009, ScienceDirect
- Nanotechnology in drug delivery 2009, Springer
- Natural products 2005, SpringerNatural products and drug discovery / Arnold L. Demain and Lixin Zhang -- Integrated approaches for discovering novel drugs from microbial natural products / Lixin Zhang -- Automated analyses of HPLC profiles of microbial extracts: a new tool for drug discovery screening / Jose R. Tormo and Juan B. Garcia -- Manipulating microbial metabolites for drug discovery and production / C. Richard Hutchinson -- Improving drug discovery from microorganisms / Chris M. Farnet and Emmanuel Zazopoulos -- Developments in strain improvement technology: evolutionary engineering of industrial microorganisms through gene, pathway, and genome shuffling / Stephen B. del Cardayr -- The discovery of anticancer drugs from natural sources / David J. Newman and Gordon M. Cragg -- Case studies in natural product optimization: novel antitumor agents derived from Taxus brevifolia and Catharanthus roseus / Jian Hong and Shu-Hui Chen --Terpenoids as therapeutic drugs and pharmaceutical agents / Guangyi Wang, Weiping Tang and Robert R. Bidigare -- Challenges and opportunities in the Chinese herbal drug industry / Wei Jia and Lixin Zhang -- Arsenic trioxide and leukemia: from bedside to bench / Guo-Qiang Chen ... [et al.] -- New methods to access microbial diversity for small molecule discovery / Karsten Zengler, Ashish Paradkar, and Martin Keller -- Accessing the genomes of uncultivated microbes for novel natural products / Asuncion Martinez ... [et al.] -- New natural product diversity from marine actinomycetes / Paul R. Jensen and William Fenical -- Novel natural products from rainforest endophytes / Gary Strobel, Bryn Daisy, and Uvidelio Castillo -- Biological, economic, ecological, and legal aspects of harvesting traditional medicine in Ecuador / Alexandra Guevara-Aguirre and Ximena Chiriboga.
- Natural products and cancer drug discovery 2013, SpringerPart 1.Natural Product Drugs and Cancer Therapeutics --The Impact of Natural Products Upon Cancer Chemotherapy /A. Ganesan --Identification and Development of Vascular Disrupting Agents: Natural Products That Interfere with Tumor Growth /Andrea T. Hooper, Frank Loganzo, Chad May and Hans-Peter Gerber --Discodermolide: Past, Present, and Future /Ross E. Longley --HDAC Inhibitors and Other Histone Modifying Natural Products as Emerging Anticancer Agents /Lilibeth A. Salvador and Hendrik Luesch --Natural Product Cytotoxins as Payloads for Antibody Drug Conjugates /Frank E. Koehn --Part 2.Advances in Natural Product Cancer Drug Discovery --Natural Product Scaffolds in Cancer Therapy /Christian P. Mang and Lars Ole Haustedt --The Role of Genetic Engineering in Natural Product-Based Anticancer Drug Discovery /Claudia Eva-Maria Unsin, Scott R. Rajski and Ben Shen --Accessing Anti-cancer Natural Products by Plant Cell Culture /Lisa M. Leone and Susan C. Roberts --Natural Products as Tools for Discovering New Cancer Targets /John A. Beutler.
- Neurotransmitter transporters 2006, Springer
- Neurotrophic factors 2014, SpringerThis book provides critical reviews of the role of neurotrophins and their receptors in a wide variety of diseases including neurodegenerative diseases like Huntington's syndrome, cognitive function, psychiatric disorders such as clinical depression, Rett syndrome, motoneurone disease, spinal cord injury, pain, metabolic disease and cardiovascular disease. It also contains contributions from leaders in the field dealing with the basic biology, transcriptional and post-translational regulation of the neurotrophins and their receptors. The present book will review all recent areas of progress in the study of neurotrophins and their biological roles.
- New drug development. 2nd ed. 2010, SpringerNew drug development -- The regulatory environment -- Drug discovery -- Nonclinical research -- Designing clinical trials -- Conducting clinical trials I: Experimental methodology -- Conducting clinical trials II: Operational execution -- Statistical analysis -- Statistical significance -- Clinical significance -- Sample size estimation -- General safety assessments -- Efficacy assessment -- Cardiac and cardiovascular safety assessments -- Manufacturing small molecule drugs and biologicals -- Postmarketing surveillance -- Main themes and concluding comments -- References -- Index.
- Nicotine psychopharmacology 2009, SpringerGlobal patterns of nicotine and tobacco consumption / S.K. Hammond -- Nicotine chemistry, metabolism, kinetics and biomarkers / N.L. Benowitz, J. Hukkanen and P. Jacob, 3rd -- Nicotine content and delivery across tobacco products / M.V. Djordjevic and K.A. Doran -- The road to discovery of neuronal nicotinic cholinergic receptor subtypes / A.C. Collins ... [et al.] -- Magnetic resonance imaging studies of cigarette smoking / A. Azizian ... [et al.] -- In vivo brain imaging of human exposure to nicotine and tobacco / A. Sharma and A.L. Brody -- Molecular and cellular mechanisms of action of nicotine in the CNS / J. Barik and S. Wonnacott -- The neuronal pathways mediating the behavioral and addictive properties of nicotine / D.J. Balfour -- Molecular genetics of nicotine metabolism / J.C. Mwenifumbo and R.F. Tyndale -- Sex differences in nicotine action / S. Pogun and G. Yararbas -- Recognising nicotine: the neurobiological basis of nicotine discrimination / J.W. Smith and I.P. Stolerman -- Effects of nicotine in experimental animals and humans: an update on addictive properties / B. Le Foll and S.R. Goldberg -- Discriminative stimulus effects of nicotine in humans / K.A. Perkins -- Rodent models of nicotine withdrawal syndrome / D.H. Malin and P. Goyarzu -- Approaches, challenges, and experience in assessing free nicotine / D.L. Ashley ... [et al.] -- Tobacco industry manipulation of nicotine dosing / G.F. Wayne and C.M. Carpenter -- Pharmacotherapy for tobacco dependence / R.V. Fant ... [et al.] -- Nicotine psychopharmacology: policy and regulatory / J.E. Henningfield and M. Zeller.
- Nimesulide--actions and uses 2005, Springer
- Nitric oxide. Part D, Nitric oxide detection, mitochondria and cell functions, and peroxynitrite reactions 2002, ScienceDirect
- Nitrite and nitrate in human health and disease 2011, Springer
- Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics 2013, ScienceDirectMachine generated contents note: I.Development of Biophar-Maceuticals Defined as Novel Biologics -- 1.Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development / Thomas R. Gelzleichter -- Introduction -- History and Evolution of Biopharmaceuticals -- Development of Diverse Biopharmaceutical Modalities -- Comparison of Small-Molecule Drugs to Biopharmaceuticals -- Summary -- References -- 2.Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological Medicines / Maggie Dempster -- Introduction -- Species Selection -- Study Design Considerations for Repeat-Dose Studies -- Immunogenicity -- Reproductive and Developmental Toxicity -- Genotoxicity and Carcinogenicity -- Special Considerations for Anticancer Drugs -- First-in-Human (Fih) Clinical Trial -- Summary -- References -- 3.Early De-risking Strategy for Novel Biotherapeutics / Beth Hinkle -- Introduction -- Establishing A Safety Profile for Biotherapeutics -- General Safety Considerations Related to Biotherapeutics -- Progress in Evaluation of Immunotoxicity -- Can We Better Address Potential Off-Target Toxicity? -- Summary -- References -- 4.Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics / Wolfgang Seghezzi -- Introduction -- Absorption, Distribution and Elimination of Biopharmaceuticals -- Disposition of Modified Molecules -- "Metabolism" and Biodistribution for Biopharmaceuticals -- Immunogenicity and impacts on PK and biodistribution -- Pharmacokinetics and Pharmacodynamics -- Preclinical to Clinical Translation -- Bioanalytics -- Drug Assays -- Biomarkers: Target Engagement Assays -- Immunogenicity Assessment: ADA Assays -- Summary -- References -- II.Development of Biosimilars -- 5.Overview of Biosimilar Therapeutics / Danuta J. Herzyk -- Introduction -- The Concept of Biosimilars -- General Considerations for Development of Biosimilars -- Biosimilar Candidates Based on Modality and Therapeutic Class -- Summary -- References -- 6.Regulatory Standards for the Approval of Biosimilar Products: A Global Review / Barbara Mounho-Zamora -- Introduction -- European Union -- Pioneer for the First Regulatory Pathway for Biosimilar Products -- The World Health Organization Guidance on Biosimilars -- Regulatory Pathway for Biosimilar Products in the United States -- Biosimilar Pathways in Other Regions -- Summary -- References -- 7.Early Characterization of Biosimilar Therapeutics / Thomas R. Gelzleichter -- Introduction -- Recombinant Insulins -- Recombinant Human Growth Hormone -- Recombinant Erythropoietins -- Recombinant Granulocyte Colony-Stimulating Factor -- Recombinant Interferons -- Low Molecular Weight Heparins -- Monoclonal Antibodies -- Other Classes -- Summary -- References -- III.Vaccines -- 8.Introduction to Vaccines and Adjuvants / Deborah L. Novicki -- Introduction -- The History of Vaccines -- The Impact of Vaccines on Human Health -- Advancements in Vaccines Technologies -- Advancements in Adjuvant Technologies -- Approved Infectious Disease Vaccines and Diseases for Which Preventive Vaccines are Still Needed -- Therapeutic Vaccines -- Product Complexity From a Quality Perspective -- Nonclinical Testing -- Clinical Testing -- Vaccine Development Using the Animal Rule -- The Anti-Vaccines Movement and Misperceptions About Vaccines and Their Safety -- Summary -- References -- 9.Global Regulatory Guidelines for Vaccines / Lisa M. Plitnick -- Introduction -- Toxicity Assessment -- Additional Toxicity Assessments -- Special Considerations -- Formulation/Delivery Devices -- Alternate Routes of Administration -- Special Considerations for Particular Types of Vaccines -- Summary -- References -- 10.Special Considerations for the Nonclinical Safety Assessment of Vaccines / Jayanthi J. Wolf -- Introduction -- De-risking Strategies for Vaccines -- Pharmacokinetics and Pharmacodynamics Assessments -- Differences in the Nonclinical Safety Assessment of Vaccines and Biopharmaceutical Drugs -- Summary -- References -- IV.Specialty Biologics and Indications -- 11.Turning the Corner with Viral-based Gene Therapy -- Development of the Rogue Biopharmaceutical / Timothy K. Maclachlan -- Introduction -- A History and Primer of Gene Therapy -- The Process of Getting Genes into Cells -- Health Authority Regulation of Gene Therapy Products -- Nonclinical Safety Studies and Regulatory Guidance -- Summary -- References -- 12.Blood Products / Vikram Arora -- Introduction -- Plasma-Derived Blood Products -- Blood Products Derived from Recombinant Technologies -- Summary -- References -- 13.Biological Therapies for Cancer / Gautham K. Rao -- Introduction -- Global Regulatory Guidances -- General Principles of Toxicology Assessments -- Nonclinical Studies and Principles of Study Design -- Specialty Toxicology Assessments -- Pharmacokinetics, Immunogenicity, and Pharmacodynamics -- Nonclinical Development of Marketed Biologies -- Recombinant Analogs of Endogeneous Human Proteins (Interferons, Cytokines, Enzymes) -- Summary -- References -- 14.Nonclinical Development of Multi-targeting Biopharmaceuticals / Anu V. Connor -- Introduction -- Scientific Rationale for Multi-Targeting Biopharmaceuticals (MTBs) -- Evolution of Technology Platforms -- General Challenges and Considerations -- Summary of Challenges -- T Cell-Dependent Bispecific Antibody (TDB) Biotherapeutics -- Dual-Targeting Antibodies -- Summary -- References -- 15.Considerations in the Development of Pluripotent Stem Cell-based Therapies / Joy A. Cavagnaro -- Introduction -- Early Decisions -- Nonclinical Development -- Translating Preclinical Data to Clinical Application -- Global Regulatory Guidance -- Summary -- References.
- Novel anticancer agents 2006, ScienceDirectA survey of novel molecular targets for anticancer drug discovery -- Microarrays: small spots produce major advances in pharmacogenomics -- Strategies to target chemotherapeutics to tumors -- QSAR and pharmacophore mapping strategies in novel anticancer drug discovery -- Applications of nuclear magnetic resonance and mass spectrometry to anticancer drug discovery -- Antisense strategies for the development of novel cancer therapeutics -- Antibodies and vaccines as novel cancer therapeutics -- Inhibitors as targets for cancer therapy -- Preclinical testing and validation of novel anticancer agents -- Surrogate end points and biomarkers for early trials of novel anticancer agents -- Regulatory considerations in clinical trials of novel anticancer drugs -- Improving the efficacy and safety of anticancer agents: the role of pharmacogenetics -- Imaging of pharmacodynamic end points in clinical trials -- Devising proof-of-concept strategies in oncology clinical trials -- Clinical trial designs for cytostatic agents and agents directed at novel molecular targets -- Cancer gene therapy clinical trials: from the bench to the clinic -- Molecular targets for radiosensitization -- Patient accrual to clinical trials.
- Novel antischizophrenia treatments 2012, SpringerThis volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
- Nutraceuticals in health and disease prevention 2001, CRCnetBASE
- Opiate receptors and antagonists 2009, Springer
- Opiate receptors. 2nd ed. 2011, Springer
- Opththalmologic drug guide 2007, Springer1Antibacterial agents --2Antifungal agents --3Antiviral agents --4Antiparasitic agents --5Antiglaucoma agents --6Neuro-ophthalmology --7Anti-inflammatory agents --8Mydriates, cycloplegics, and reversal agents --9Lubricants and viscoelastics --10Miscellaneous conditions --11Anti-angiogenesis agents --12Contact lens.
- Optimization in drug discovery 2004, Springer ProtocolspKa, solubility and lipophilicity: assessing physicochemical properties of lead compounds / Yushen Guo and Hong Shen -- Use of caco-2 cell monolayers to study drug absorption and metabolism / Ming Hu ... [et al.] -- Absorption screening using the PAMPA approach / Jeffrey A. Ruell and Alex Avdeef -- In situ single-pass perfused rat intestinal model for absorption and metabolism / Eun Ju Jeong ... [et al.] -- In vitro permeation study with bovine brain microvessel endothelial cells / Sung-Hack Lee ... [et al.] -- An enzymatic microplate assay for testing P-glycoprotein substrates and inhibitors / S. Orlowski, J. Nugier and Eric Ezan -- Evaluation of drug-transporter interactions using in vitro cell models / Yaming Su and Patrick J. Sinko -- Plasma protein-binding methods in drug discovery / Lucinda H. Cohen --Isothermal titration calorimetry characterization of drug-binding energetics to blood proteins / Gary W. Caldwell and Zhengyin Yan -- Metabolic stability assessed by liver microsomes and hepatocytes / David C. Ackley, Kevin T. Rockich, and Timothy R. Baker -- In vitro drug metabolite profiling using hepatic S9 and human liver microsomes / Wu-Nan Wu and Linda A. McKown --In vitro identification of UDP-glucuronosyltransferases involved in drug metabolism / Michael H. Court -- In vitro CYP induction in human hepatocytes / Daniel R. Mudra and Andrew Parkinson -- High-throughput screening of human cytochrome P450 inhibitors using fluorometric substrates: methodology for 25 enzyme/substrate pairs / David M. Stresser -- Evaluation of cytochrome P450 inhibition in human liver microsomes / Zhengyin Yan and Gary W. Caldwell -- Identification of CYP mechanism-based inhibitors / Amin A. Nomeir, Jairam Palamanda, and Leonard Favreau --Detection of DNA adducts by 32P-postlabeling analysis / Naomi Suzuki, Padmaja M. Prabhu, and Shinya Shibutani -- Covalent DNA adduct formation mediated by cytochrome P450 / Marie Stiborová -- Application of in vitro comet assay for genotoxicity testing / Bojana Zegura and Metka Filipic -- Assessing DNA damage using a reporter gene system / Xuming Jia and Wei Xiao -- Improvement of the Ames test using human liver S9 preparation / Atsushi Hakura, Satoshi Suzuki, and Tetsuo Satoh -- Screening for chemical mutagens using the mouse lymphoma assay / Tao Chen and Martha M. Moore -- A high throughput binding assay for HERG / Keith Finlayson and John Sharkey -- In vitro drug metabolism: thiol conjugation / Wei Tang and Randy R. Miller -- In vitro screening assay of the reactivity of acyl glucuronides / Sébastien Bolze.
- Oral delivery of macromolecular drugs 2009, Springer
- Oral mucositis 2012, SpringerTreatment tolerance is a challenge for most cancer patients, and it is therefore essential that healthcare professionals (HCP) are quick to recognize adverse events and implement management strategies to address them. This pocket book provides an in-depth guide to the epidemiology, diagnosis and management of oral mucositis, a common adverse event of chemotherapy.
- PARP as a therapeutic target 2002, CRCnetBASE
- Pasteurella multocida 2012, SpringerPasteurella multocida: Diseases and Pathogenesis /I. W. Wilkie, M. Harper, J. D. Boyce and B. Adler --Pathogenomics of Pasteurella multocida /J. D. Boyce, T. Seemann, B. Adler and M. Harper --The Key Surface Components of Pasteurella multocida: Capsule and Lipopolysaccharide /Marina Harper, John D. Boyce and Ben Adler --Pasteurella multocida and Immune Cells /Katharina F. Kubatzky --Molecular Biology of Pasteurella multocida Toxin /Joachim H. C. Orth and Klaus Aktories --Pasteurella multocida Toxin Interaction with Host Cells: Entry and Cellular Effects /Brenda A. Wilson and Mengfei Ho --Swine Atrophic Rhinitis Caused by Pasteurella multocida Toxin and Bordetella Dermonecrotic Toxin /Yasuhiko Horiguchi --The Pasteurella multocida Toxin: A New Paradigm for the Link Between Bacterial Infection and Cancer /Alistair Lax.
- Path from biomarker discovery to regulatory qualification 2013, ScienceDirectThe Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book-it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science. Contains a collection of experiences of different groups taking different types of biomarkers to different levels of qualification and provides insightful case studies of an important area of regulatory science Focuses on practical advice, concepts, strategies and overall outcomes to support those working toward biomarker qualification for clinical use Offers a valuable resource for members of the regulatory, pharmaceutical and biomarker development communities.
- Pathobiology of cancer regimen-related toxicities 2013, Springer
- Pediatric clinical pharmacology 2011, Springer
- Peptide-based drug design 2008, Springer ProtocolsPeptide-based drug design : here and now / Laszlo Otvos, Jr. -- Strategies for the discovery, isolation, and characterization of natural bioactive peptides from the immune system of invertebrates / Philippe Bulet -- Sequence analysis of antimicrobial peptides by tandem mass spectrometry / Christin Stegemann and Ralf Hoffmann -- The spot technique : synthesis and screening of peptide macroarrays on cellulose membranes / Dirk F.H. Winkler and William D. Campbell -- Analysis of A[beta] interactions using ProteinChip technology / Eleni Giannakis ... [et al.] -- NMR in peptide drug development / Jan-Christoph Westermann and David J. Craik -- Molecular dynamics simulations of peptides / Jeffrey Copps, Richard F. Murphy and Sandor Lovas -- Short linear cationic antimicrobial peptides : screening, optimizing, and prediction / Kai Hilpert, Christopher D. Fjell and Artem Cherkasov -- Investigating the mode of action of proline-rich antimicrobial peptides using a genetic approach : a tool to identify new bacterial targets amenable to the design of novel antibiotics / Marco Scocchi ... [et al.] -- Serum stability of peptides / Håvard Jenssen and Stein Ivar Aspmo -- Preparation of glycosylated amino acids suitable for Fmoc solid-phase assembly / Mare Cudic and Gayle D. Burstein -- Synthesis of O-phosphopeptides on solid phase / David Singer and Ralf Hoffmann -- Peptidomimetics : Fmoc solid-phase pseudopeptide synthesis / Predrag Cudic and Maciej Stawikowski -- Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines / Brandon Y. Chua, Weiguang Zeng and David C. Jackson -- Synthesis of a multivalent, multiepitope vaccine construct / Laszlo Otvos, Jr. -- Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins / Marina V. Backer ... [et al.].
- Peptides for youth 2009, Springer
- Percutaneous absorption. 4th ed. 2005, CRCnetBASE
- Pharmaceutical biotechnology 2009, SpringerTranslational medicine: a paradigm shift in modern drug discovery and development: the role of biomarkers / Mark Day, J. Lynn Rutkowski, and Giora Z. Feuerstein -- Natural products in drug discovery: present status and perspectives / Gabriella Molinari -- Protein pharmaceuticals: discovery and preclinical development / Davinder S. Gill -- The role of nanobiotechnology in drug discovery / Kewal K. Jain -- Conotoxin venom peptide therapeutics / Richard J. Lewis -- Shark novel antigen receptors: the next generation of biologic therapeutics? / Caroline Barelle, Davinder Gill, and Keith Charlton -- Immune interventions of human diseases through toll-like receptors / Cevayir Coban, Ken J. Ishii, and Shizuo Akira -- Genome-based vaccine development: a short cut for the future / Danilo Gomes Moriel ... [et al.] -- The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections? / Carmen Giefing, Eszter Nagy, and Alexander von Gabain -- HSV as a vector in vaccine development and gene therapy / Peggy Marconi ... [et al.] -- Virus-like particles as a vaccine delivery system: myths and facts / Polly Roy and Rob Noad -- Applications of bacterial ghosts in biomedicine / Petra Lubitz, Ulrike Beate Mayr, and Werner Lubitz -- Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design / Thomas Ebensen and Carlos A. Guzmøn -- Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS / Aurelio Cafaro ... [et al.] -- New strategies to overcome the drawbacks of currently available flu vaccines / Epifanio Fichera ... [et al.].
- Pharmaceutical perspectives of cancer therapeutics 2009., Springer
- Pharmaceutical stability testing to support global markets 2010, SpringerContains proceedings of the AAPS Stability Workshop.
- Pharmaco-complexity 2011, Springer
- Pharmacodynamic basis of herbal medicine 2002, CRCnetBASE
- Pharmacodynamic basis of herbal medicine. 2nd ed. 2007, CRCnetBASE
- Pharmacogenomic testing in current clinical practice 2011, Springer
- Pharmacogenomics 2005, Springer Protocols
- Pharmacogenomics and personalized medicine 2008, Springer ProtocolsChallenges, opportunities, and evolving landscapes in pharmacogenomics and personalized medicine : an industry perspective / Nadine Cohen and Theresa Frangiosa -- Implementation of pharmacogenomic sample collection in clinical trials / Deborah Sokol Ricci and Monique Franc -- Pharmacogenomics : the regulatory environment and labeling implications / Myong-Jin Kim ... [et al.] -- Applications of pharmacogenomics in drug discovery / Duncan McHale -- Applications of pharmacogenomics in clinical trials / Monique Franc -- Pharmacogenomics applications in drug metabolism : from genotyping to drug label-challenges? / Ann K. Daly -- The genetics of adverse drug reactions : promises and problems / Martin Armstrong -- Strategies and resources for marker selection and genotyping in genetic association studies / Nicole Soranzo, Dong-Jing Fu, and Qingqin S. Li -- Study design and statistical issues in pharmacogenetics research : from candidate genes to genome-wide screens / Nicholas J. Schork, Nathalie Malo, and Eric J. Topol -- Holy SNP, Batman! / Reyna Favis -- Predictive biomarker classifiers in the design of pivotal clinical trials / Richard Simon -- Translation of biomarkers into clinical utility / William L. Trepicchio and George Mulligan -- Pharmacogenomic study feasibility assessment and pharmaceutical business decision-making / Monique Franc and Theresa Frangiosa -- Co-development of drugs and pharmacogenomics-based diagnostics in oncology / Jeffrey S. Ross -- Pharmacogenomics applications in epilepsy / Chantal Depondt -- Pharmacogenomics in Alzheimer's disease / Ramón Cacabelos -- Pharmacogenomics applications in psychiatric disorders / Todd Lencz and Anil K. Malhotra -- Pharmacogenomics in HIV disease / Amalio Telenti -- Pharmacogenomics and cardiovascular drugs / Gérard Siest ... [et al.] -- Pharmacogenomic applications in children / Susan F.A. Grant and Hakon Hakonarson -- Pharmacogenomics of rare and monogenic disorders / Paul D. Maher.
- Pharmacogenomics in clinical therapeutics 2012, WileyPharmacogenomics principles : introduction to personalized medicine / Parvaz Madadi, and Gideon Koren -- Traditional therapeutic drug monitoring and pharmacogenomics : are they complementary? / Christine Snozek, Loralie J. Langman, and Amitava Dasgupta -- Pharmacogenomics aspect of warfarin therapy / Matthew D. Krasowski -- Pharmacogenetics and cancer chemotherapy / Christine L.H. Snozek -- Pharmacogenomic considerations in anesthesia and pain management / Christine Formea, Wayne T. Nicholson -- Pharmacogenomics of immunosuppressants / Nicolas Picard and Pierre Marquet -- Pharmacogenomics of cardiovascular drugs / Linnea M. Baudhuin -- Pharmacogenomics aspect of antiretroviral therapy / Natella Y. Rakhmanina and John N. van den Anker -- Pharmacogenetics of psychoactive drugs / Jorge L. Sepulveda -- Pharmacogenomic aspects of adverse drug-drug interactions / Loralie J. Langman and Christine Snozek -- Microarray technology and other methods in pharmacogenomics testing / Jorge L. Sepulveda -- Pharmacogenetic testing in the clinical laboratory environment / Mark P. Borgman and Mark W. Linder.
- Pharmacogenomics in drug discovery and development 2008, Springer Protocols
- Pharmacogenomics of alcohol and drugs of abuse 2012, CRCnetBASECh. 1. Pharmacogenomics principles of alcohol and DOA / Christine L.H. Snozek and Loralie J. Langman -- ch. 2. Alcohol : use and abuse / Amitava Dasgupta -- ch. 3. Slate and trait makers of alcohol abuse / Joshua Bornhorst ... [et al.] -- ch. 4. Introduction to drugs of abuse / Larry Broussard and Catherine Hammett-Stabler -- ch. 5. Pharmacogenomics of amphetamine and related drugs / Steven C. Kazmierczak -- ch. 6. Pharmacogenomics of cocaine / Loralie J. Langman and Christine L.H. Snozek -- ch. 7. Genetic aspect of marijuana metabolism and abuse / Pradip Datta -- ch. 8. Genetic aspect of opiate metabolism and addiction / Jorge L. Sepulveda -- ch. 9. Pharmacogenomics aspects of addiction treatment / F. Gerard Moeller -- ch. 10. Methodologies in pharmacogenetics testing / Jorge L. Sepulveda.
- Pharmacokinetic-pharmacodynamic modeling and simulation 2006, Springer
- ch. 1. Physicochemistry -- ch. 2. Pharmacokinetics -- ch. 3. Absorption -- ch. 4. Distribution -- ch. 5. Clearance -- ch. 6 Renal clearance -- ch. 7. Metabolic (hepatic) clearance -- ch. 8. Toxicity -- ch. 9. Inter-species -- ch. 10. High(er) throughput ADME studies.
- Pharmacokinetics and pharmacodynamics of abused drugs 2008, CRCnetBASE
- Pharmacokinetics in drug discovery and development 2002, CRCnetBASESECTION I. Basic Principles -- Chapter 1. Basic Principles / Ronald D. Schoenwald -- SECTION II. Industrial and Regulatory Applications -- Chapter 2. PK/PD Approach / Honghui Zhou -- Chapter 3. Pharmacokinetics and Metabolism in Drug Discovery and Preclinical Development / Nishit B. Modi -- Chapter 4. Phase I, II, and III FDA Submissions / Mark G. Eller -- Chapter 5. Bioavailability and Bioequivalence / Veneeta Tandon -- SECTION III. Clinical Applications -- Chapter 6. General Approaches to Clinical Pharmacokinetic Monitoring / Ronald A. Herman -- Chapter 7. Aminoglycosides and Other Antibiotics / Michael E. Klepser and Erika J. Ernst -- Chapter 8. Cardiovascular Agents / John M. Dopp and Bradley G. Phillips -- Chapter 9. Psychotropic Agents / Paul J. Perry -- Chapter 10. Theophylline / Bernd Meibohm -- Chapter 11. Anticonvulsant Agents / Gail D. Anderson -- SECTION IV. Research Applications -- Chapter 12. Classical Modeling / David W A. Bourne -- Chapter 13. Noncompartmental Modeling: An Overview / Ronald A. Herman -- Chapter 14. Physiologically Based Pharmacokinetic Models / James M. Gallo -- Chapter 15. Population Pharmacokinetics / Jeffrey S. Barrett -- Chapter 16. The Linear Systems Approach / Peter Veng-Pedersen -- Index.
- Pharmacological mechanisms in Alzheimer's therapeutics 2008, Springer
- Pharmacological potential of selected natural compounds in the control of parasitic diseases 2013, SpringerThe natural world with a large number of terrestrial and marine plants and lower organisms is a great source of bioactive compounds historically used as remedies in various diseases. Within the last decade, such compounds became more attractive targets for pharmacologists and the pharmaceutical industry in drug development projects. This volume presents the pharmacological potential of chemically defined natural compounds obtained from plants, fungi, algae and cyanobacteria with antiparasitic activity, that have been tested against various endo-parasitic protozoan and helminth species. --Source other than Library of Congress.
- Pharmacological treatment of acute coronary syndromes 2014, SpringerCardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs.
- Pharmacology 2009, ScienceDirect
- Pharmacology and pharmacokinetics 2010, SpringerPharmacology -- Pharmacokinetic Principles -- Introduction to Specialist Therapeutics.
- Pharmacology and physiology for anesthesia 2013, ScienceDirectFulltext ClinicalKey"Better understand the complexities of pharmacology and physiology relevant to your practice with the brand-new medical reference book, Anesthetic Pharmacology and Physiology. Drs. Hugh Hemmings and Talmage Egan provide the clinical insights you need to effectively administer anesthesia, ensuring patient safety and the most optimal outcomes. Access comprehensive, continually updated research on the physiology of organ systems and clinical topics in the pharmacology of anesthetic drugs. Quickly and easily reference the information you need through user-friendly tables, figures, and algorithms, all presented in lavish full color throughout. Understand the molecular mechanism of drug actions and identify key drug interactions that may complicate anesthesia with dedicated sections on these key areas"--Provided by publisher.
- Pharmacology and vitreoretinal surgery 2009, Karger
- Pharmacology in drug discovery. 1st ed. 2012, ScienceDirectChapter 1. Pharmacology: The Chemical Control of Physiology -- Chapter 2. Drug Affinity and Efficacy -- Chapter 3. Predicting Agonist Effect -- Chapter 4. Drug Antagonism: Orthosteric Drug Effects -- Chapter 5. Allosteric Drug Effects -- Chapter 6. Enzymes as Drug Targets -- Chapter 7. Pharmacokinetics I: Permeation and Metabolism -- Chapter 8. Pharmacokinetics II: Distribution and Multiple Dosing -- Chapter 9. In Vivo Pharmacology -- Chapter 10. Safety Pharmacology -- Chapter 11. Answers to Chapter Questions -- Chapter 12. Derivations and Proofs.
- Pharmacology of Bombax ceiba Linn 2012, Springer"This work is the first monograph devoted solely to Bombax ceiba, popularly known as the Red Silk Cotton Tree. Consisting of seven chapters, it covers all relevant aspects of this plant, from its historical and spiritual importance, to its botanical characterization, pharmacognostical details and ethnobiological uses, to its scientific validation in various animal and human studies. Each part of the tree is of medicinal value and possesses many novel chemical constituents such as shamimicin, bombasin, bombamalone, bombamaloside etc. along with other bioactive secondary metabolites. The book presents the chemical structures of the most important constituents and highlights various pharmacological activities, predominantly antioxidant, anti-inflammatory, anti-mutagenic, hypoglycemic, hypotensive, hepatoprotective and fibrinolytic, which may prove to be a source for the development of a novel phyto-pharmaceutical agent to treat diabetes, heart disease and cancer. In addition, separate chapters deal with the commercial and ecological significance of B. ceiba, as well as a case study on its conservation. Numerous color illustrations are included to identify the plant and to justify its nickname, the “Little Bird's Cafeteria”."--Publisher's website.
- Pharmacology of neurotransmitter release 2008, Springer
- Pharmacology primer. 3rd ed. 2009, ScienceDirectWhat is pharmacology? -- How different tissues process drug response -- Drug-receptor theory -- Pharmacological assay formats : binding -- Agonists : the measurement of affinity and efficacy in functional assays -- Orthosteric drug antagonism -- Allosteric drug antagonism -- The process of drug discovery -- Pharmacokinetics -- Target- and system-based strategies for drug discovery -- "Hit" to drug : lead optimization -- Statistics and experimental design -- Selected pharmacological methods -- Exercises in pharmacodynamics and pharmacokinetics.
- Pharmacoresistance in epilepsy 2013, SpringerAlthough more than 10 new antiepileptic drugs have been developed in the past decade, epilepsy remains resistant to drug therapy in about one-third of patients, many of whom struggle with the disease their entire lives. Managing these patients is a challenge and requires a structured multidisciplinary approach. The book includes chapters on all issues related to pharmacoresistance in epilepsy, and describes recent developments in the pathogenesis and treatment of this disorder. It addresses abnormalities in inhibitory mechanisms, epilepsy-related changes to the immune system, development of pharmacoresistance caused by chronic exposure to antiepileptic drugs, and novel therapeutic strategies for preventing or slowing down the progression of the disease. Clinicians and basic scientists alike will find up-to-date information on the development of pharmacoresistance, as well as reviews of mechanisms associated with epilepsy that may help them consider novel strategies for preventing the development of pharmacoresistance in the first place. The book also features information on new therapeutic strategies for control of epilepsy, such as transcutaneous electrical stimulation and virtual screening of new antiepileptic drugs. Pharmacoresistance in Epilepsy: From Genes and Molecules to Promising Therapies is useful to anyone working in the field, whether they're studying epilepsy in the lab or treating it in a doctor's office.
- Pharmacotherapy of pulmonary hypertension 2013, SpringerDefinition and classification of pulmonary hypertension / Marc Humbert, David Montani, Oleg V. Evgenov, and Gérald Simonneau -- Pulmonary hypertension: pathophysiology and signaling pathways / Bradley A. Maron and Joseph Loscalzo -- Pulmonary hypertension: pathology / Peter Dorfmüller -- Pulmonary hypertension: biomarkers / Christopher J. Rhodes, John Wharton, and Martin R. Wilkins -- Rodent models of group 1 pulmonary hypertension / John J. Ryan, Glenn Marsboom, and Stephen L. Archer -- General supportive care / Ioana R. Preston -- Calcium-channel blockers in pulmonary arterial hypertension / Marie-Camille Chaumais, Elise Artaud Macari, and Olivier Sitbon -- Prostacyclins / Horst Olschewski -- Endothelin Receptor Antagonists / Martine Clozel, Alessandro Maresta, and Marc Humbert -- Phosphodiesterase-5 inhibitors / Barbara A. Cockrill and Aaron B. Waxman -- Inhaled nitric oxide for the treatment of pulmonary arterial hypertension / Steven H. Abman -- Soluble guanylate cyclase stimulators in pulmonary hypertension / Johannes-Peter Stasch and Oleg V. Evgenov -- Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction / Michael G. Risbano and Mark T. Gladwin -- Rho-kinase inhibitors / Yoshihiro Fukumoto and Hiroaki Shimokawa -- Serotonin transporter and serotonin receptors / Serge Adnot, Amal Houssaini, Shariq Abid, Elisabeth Marcos, and Valérie Amsellem -- Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension / Eva Berghausen, Henrik ten Freyhaus, and Stephan Rosenkranz -- Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension / Ly Tu and Christophe Guignabert -- Anti-inflammatory and immunosuppressive agents in PAH / Jolyane Meloche, Sébastien Renard, Steeve Provencher, and Sébastien Bonnet -- Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application / Reshma S. Baliga, Raymond J. MacAllister, and Adrian J. Hobbs -- Pulmonary hypertension: novel pathways and emerging therapies inhibitors of cGMP and cAMP metabolism / Yassine Sassi and Jean-Sébastien Hulot -- Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers) / Geoffrey Watson, Eduardo Oliver, Lan Zhao, and Martin R. Wilkins -- Pulmonary hypertension: current management and future directions / Lewis J. Rubin.
- Phosphodiesterases as drug targets 2011, Springer
- Phosphoinositide 3-kinase in health and disease v. 1- 2=, 2011, Springerv. 2, 2011 SpringerVol. 1 / (ix, 306 p.) -- v. 2. / (x, 301 p.).
- Phytochemicals 2004, CRCnetBASEAbsorption and metabolism of anthocyanins and other phenolics in human subjects / Ronald L. Prior -- Absorption and metabolism of the dietary phytochemical, quercetin / Gary Williamson -- Pharmacokinetics and bioavailability of green tea catechins / H-H. Sherry Chow -- The importance of in vivo metabolism of polyphenols and their biological action / Stephen Barnes -- Cancer prevention by phytochemicals, modulation of cell cycle / Diane F. Birt -- Cancer chemoprevention by phytopolyphenols including flavanoids and flavonoids through modulating signal transduction pathways / Jen-Kun Lin -- Gene regulation by glucosinolate hydrolysis products / Elizabeth H. Jeffery -- Healthy food vs. phytosterol fortified foods for primary prevention of coronary artery disease / Douglas S. Lewis -- Vascular effects of resveratrol / Joseph M. Wu -- Development of a mixture of dietary carotenoids as cancer chemopreventive agents: C57BL/6J mice as a useful animal model for efficacy studies with carotenoids / Frederick Khachik -- Chemoprevention of colon cancer by curcumin / Bandaru S. Rdddy.
- Phytochemicals in health and disease 2004, CRCnetBASENutritional genomics / Ruan M. Elliott, James R. Bacon, and Yongping Bao -- Methods to study bioavailability of phytochemicals / Birgit Holst and Gary Williamson -- Characterization of polyphenol metabolites /Andrea J. Day, Joseph A. Rothwell, and Michael R.A. Morgan -- Microarray profiling of gene expression patterns of genistein in tumor cells / Ching Li and Biehuoy Shieh -- Gene regulatory activity of Ginkgo biloba L. / Gerald Rimbach, Rainer Cermak, and Siegfried Wolffram -- Cancer chemoprevention with sulforaphane, a dietary isothiocyanate / Yuesheng Zhang -- Phytochemicals protect against heterocyclic amine-induced DNA adduct formation / Yongping Bao and James R. Bacon -- Organosulfur-garlic compounds and cancer prevention / John Milner -- Polymethylated flavonoids: cancer preventive and therapeutic potentials derived from anti-inflammatory and drug metabolism-modifying properties / Akira Murakami and Hajime Ohigashi -- Biochemical and molecular mechanisms of cancer chemoprevention by tea and tea polyphenols / Jen-Kun Lin -- The role of flavonoids in protection against cataract / Julie Sanderson and W. Russell McLauchlan -- Effects of oltipraz on phase 1 and phase 2 xenobiotic-metabolizing enzymes / Sophie Langouet, Fabrice Morel and Andre Guillouzo -- Future perspectives in phytochemical and health research / Yongping Bao and Roger Fenwick.
- Phytopharmaceuticals in cancer chemoprevention 2005, CRCnetBASE
- Plant-produced microbial vaccines 2009, SpringerPlant vaccines: an immunological perspective / D.C. Hooper -- Display of peptides on the surface of tobacco mosaic virus particles / M.L. Smith ... [et al.] -- Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality / S. Chebolu and H. Daniell -- Production of antibodies in plants: approaches and perspectives / K. Ko, R. Brodzik and Z. Steplewski -- Plant production of veterinary vaccines and therapeutics / R.W. Hammond and L.G. Nemchinov -- Plant-based oral vaccines: results of human trials / C.O. Tacket.
- Pocket guide to critical care pharmacotherapy 2008, Springer
- Pocket handbook of GI pharmacotherapeutics 2009, Springer
- Polymers in drug delivery 2006, CRCnetBASE
- Polypharmacy in psychiatry practice 2013, SpringerFulltext Vol. 2 SpringerAlthough monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem.
- Polyvinylpyrrolidone excipients for pharmaceuticals 2005, Springer
- Practical guide to drug development in academia 2014, SpringerWritten by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed "too early" to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest.
- A. Introduction -- B. Passive or active pharmacovigilance? -- C. Spontaneous reporting -- D. Cohort event monitoring -- E. Data processing -- F. Special types of event -- G. Relationship/causality assessment -- H. Signal identification -- I. Strengthening the signal -- J. Identifying risk factors -- K. Analyses -- L. Differences between spontaneous reporting and cohort event monitoring -- M. Organization -- N. Communication -- Annex.
- Principles of immunopharmacology. 3rd rev. and extended ed. 2011, Springer
- Prodrugs 2007, Springer
- Progress in drug research v. 62-, 2005-, Springer
- Protein crystallography in drug discovery 2004, Wileych. 1. Molecular Recognition of Nuclear Hormone Receptor-Ligand Complexes / Dr. Robert E. Babine, p. 1-46 -- ch. 2. Kinases / Jerry L. Adams, James Veal and Lisa Shewchuk, p. 47-81 -- ch. 3. The Proteasome as a Drug Target / Tsunehiro Mizushima and Tomitake Tsukihara, p. 83-98 -- ch. 4. Antibiotics and the Ribosome / Jeffrey L. Hansen, p. 99-125 -- ch. 5. Structure-Based Design of Cathepsin K Inhibitors / Daniel F. Veber and Maxwell D. Cummings, p. 127-146 -- ch. 6. Structure-Based Design of Potent and Selective Cdk4 Inhibitors / Teruki Honma, p. 147-170 -- ch. 7. Crystallization and Analysis of Serine Proteases with Ecotin / Sandra M. Waugh and Robert J. Fletterick, p. 171-186 -- ch. 8. X-Ray Crystallography in the Development of Orthogonal Ligand-Receptor Pairs / Donald F. Doyle and Lauren J. Schwimmer, p. 187-207 -- ch. 9. Engineering Proteins to Promote Crystallization / Lei Jin and Robert E. Babine, p. 209-216 -- ch. 10. High-Throughput Crystallography / Harren Jhoti, p. 217-233 -- ch. 11. Micro-Crystallization / Carl L. Hansen, Morten Sommer, Kyle Self, James M. Berger and Stephen R. Quake, p. 235-255.
- Protein-protein interactions as new drug targets 2008, Springer
- Proteomics and protein-protein interactions 2005, Springer
- Proteopathic seeds and neurodegenerative diseases 2013, SpringerThe misfolding and aggregation of specific proteins is an early and obligatory event in many of the age-related neurodegenerative diseases of humans, and appears to occur many years before the onset of clinical symptoms. The initial cause of this pathogenic cascade and the means whereby disease spreads through the nervous system, remain uncertain. A recent surge of research, first instigated by pathologic similarities between prion disease and Alzheimer's disease, has increasingly implicated corruptive protein templating, or seeding, as a prime factor in the neurodegenerative process. The prion-like corruption of proteins also characterizes such clinically and etiologically diverse neurological disorders as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Understanding the misfolding, aggregation, trafficking and pathogenicity of affected proteins thus could reveal universal principles and common therapeutic targets for some of the most devastating and intractable human brain disorders.
- Protocols for in vitro cultures and secondary metabolite analysis of aromatic and medicinal plants 2009, Springer ProtocolsEstablishment of adventitious root cultures of Echinacea purpurea for the production of caffeic acid derivatives / K.Y. Paek, H.N. Murthy and E.J. Hahn -- In vitro propagation of Rauwolfia serpentina using liquid medium, assessment of genetic fidelity of micropropagated plants, and simultaneous quantitation of reserpine, ajmaline, and ajmalicine / M.K. Goel ... [et al.] -- Medicinal properties, in vitro protocols and secondary metabolite analyses of Scots pine / H. Haggman ... [et al.] -- Saussurea medusa cell suspension cultures for flavonoid production / C.Z. Liu and P.K. Saxena -- Large-scale in vitro multiplication of Crataeva nurvala / S.B. Babbar, N. Walia and A. Kaur -- Bilberry in vitro protocols and analyses of phenolic compounds / L. Jaakola ... [et al.] -- In vitro propagation of two tuberous medicinal plants: Holostemma ada-kodien and Ipomoea mauritiana / S.P. Geetha ... [et al.] -- In vitro production of gymnemic acid from Gymnema sylvestre (Retz) R. Br. Ex Roemer and Schultes through callus culture under abiotic stress conditions / A.B. Ali Ahmed, A.S. Rao and M.V. Rao -- Establishment of plant regeneration and cryopreservation system from zygotic embryo-derived embryogenic cell suspension cultures of Ranunculus kazusensis / S.W. Kim and M.J. Oh -- In vitro culture and secondary metabolite isolation in bryophytes / A. Sabovljevic, M. Sabovljevic and N. Jockovic -- Micropropagation and in vitro conservation of vanilla (Vanilla planifolia Andrews) / M. Divakaran and K.N. Babu -- Protocol for in vitro regeneration and marker glycoside assessment in Swertia chirata Buch-Ham / S. Koul ... [et al.] -- Protocols for establishment of an in vitro collection of medicinal plants in the genus Scutellaria / I.B. Cole, F.T. Farooq and S.J. Murch -- Protocols for in vitro culture and phytochemical analysis of Phyllanthus species (Euphorbiaceae) / E. Catapan ... [et al.] -- In vitro clonal propagation of Asparagus racemosus, a high value medicinal plant / S. Saxena and N. Bopana -- Micropropagation of Penthorum chinense through axillary buds / J. Yang and Z.S. Peng -- Spontaneous plant regeneration and production of secondary metabolites from hairy root cultures of Centaurium erythraea Rafn / A. Subotic ... [et al.] -- Transgenic Hypericum perforatum / G. Franklin, M.M. Oliveira and A.C. Dias -- Agrobacterium-mediated transformation of Ruta graveolens L / K. Lievre ... [et al.] -- Gene expression profiling in Taxus baccata L. seedlings and cell cultures / K. Brun akova and J. Kosuth -- Catapol production in Chinese foxglove (Rehmannia glutinosa Libos.) hairy roots transformed with Agrobacterium rhizogenes ATCC15834 / S.J. Hwang -- Identification of medicinal plants and plant sequences: multiplexed MLPA assay / R.A. Barthelson -- Isolation of microsatellites from Catharanthus roseus (L.) G. Don using enriched libraries / S. Bhatia and B. Shokeen -- Production of cinnamyl glycosides in compact callus aggregate cultures of Rhodiola rosea through biotransformation of cinnamyl alcohol / Z. Gyorgy and A. Hohtola -- Spearmint plantlet culture system as a means to study secondary metabolism / B. Tisserat, M. Berhow and S.F. Vaughn -- Bioreactor production of secondary metabolites from cell cultures of periwinkle and sandalwood / J.V. Valluri -- Camptothecin production by in vitro cultures and plant regeneration in Ophiorrhiza species / T. Asano ... [et al.] -- Metabolomic analysis of Ocotea odorifera cell cultures: a model protocol for acquiring metabolite data / M. Maraschin ... [et al.] -- Production of 9-methoxycanthin-6-one from callus cultures of (Eurycoma longifolia Jack) Tongkat Ali / M. Maziah and N. Rosli -- Plant secondary metabolism in altered gravity / L.K. Tuominen, L.H. Levine and M.E. Musgrave -- The role of biotechnology in the production of the anticancer compound podophyllotoxin / H. Lata, C.S. Mizuno and R.M. Moraes.
- Quantification addendum. 3rd ed. 2010, WHO
- Quantitative drug design. 2nd ed. 2010, CRCnetBASEOverview of quantitative drug design -- Noncovalent interactions in biological systems -- Preparation of 3D structures of molecules for 3D QSAR -- Calculating physical properties of molecules -- Biological data -- Form of equations that relate potency and physical properties -- Statistical basis of regression and partial least-squares analysis -- Strategy for the statistical evaluation of a data set of related molecules -- Detailed examples of QSAR calculations on erythromycin esters -- Case studies -- Methods to approach other structure-activity problems.
- Radiopharmaceuticals 2011, CRCnetBASE"This comprehensive overview details the process of radiopharmaceutical development, from cellular studies to animal experiments to the design and implementation of clinical trials. It examines the relative benefits of various radiopharmaceuticals and provides guidance on dose estimation and agent selection. Utilizing figures of merit for quantitative assessment, it covers standard medical internal radiation dose (MIRD), absorbed dose method for imaging agents, vivo methods for obtaining activity data, errors of activity estimation techniques, phantom-based and patient-based dose estimates and their associated uncertainties, and options available to clinical physicists. Supported by numerous examples from clinical trials, it discusses two and three dimensional estimation processes, including modern hybrid scanners such as SPECT/CT and PET/CT"--Provided by publisher.
- 3D cell-based biosensors in drug discovery programs — Dose finding by the continual reassessment method (100)
- Drug absorption studies — Methylxanthines (100)
- Microbial genomics and drug discovery — Radiopharmaceuticals (100)
- Raman and SERS investigations of pharmaceuticals — What your patients need to know about psychiatric medications (39)
- Harrison's Principles of Internal Medicine
- AAP Red Book Online
- Robbins & Cotran Pathologic Basis of Disease
- Sabiston Textbook of Surgery
- Nelson's Textbook of Pediatrics
- Surgical Exposures in Orthopaedics
- Mandell, Douglas, & Bennett's Principles & Practice of Infectious Diseases
- Red Book Online
- ICU Book
- Primary Care Medicine
- Campbell-Walsh Urology
Shortcut to Licensed Content
Bookmark on other websites
- Select "Add to Favorites" (click “Continue” if you see a security alert)
- From the "Create in" menu, select “Links” (IE7) or “Favorites Bar” (IE8, IE9) to install
- Once installed it will look like this
- Click "Bookmark on Lane" to bookmark any webpage
- Your saved bookmark will appear on this page
What is it?
This shortcut (Lane proxy bookmarklet) gives you access to resources licensed by the library even when you're not coming from a Lane or a Stanford IP address.
While we'd like Lane to be your gateway to our licensed content, we recognize that links to books, articles and journals come from a variety of different sources (Google, your email, RSS reader, etc.).
When installed, it will look your browser bookmark.
At the page you would like to proxy, click the "Lane Gateway to Licensed Content" to invoke it.
If Lane licenses that content, you'll get access as if you were on campus.
How does it work?
This allows you to view the URL as though you were on campus, giving you access to materials licensed for use by the Stanford academic community.
If you're not authenticated, you'll be prompted for your SUNetID and password.
Don't see the Toolbar, Bookmarks, or Links or Favorites bar?
From the "View" menu, select "Toolbars" & choose "Bookmarks Toolbar"
From the "View" menu, choose "Show Bookmarks Bar"
From the "View" menu, choose "Always Show Bookmarks Bar"
- Right-click in a clear area near the browser address bar
- In the menu, check a box next "Links" (IE7) or "Favorites Bar" (IE8, IE9)
- Managing IE Favorites
This shortcut (Lane proxy bookmarklet) only works with resources Lane has licensed and configured to work with our proxy server.
If invoked on a resource we do not license and/or have not yet configured, you will see an error message:
The Lane proxy server cannot complete your request because this host has not been configured properly.
We make no attempt to configure our proxy server for every resource, only those we license and for which a Stanford IP address grants access.
Drag this button onto your browser toolbar to install.
- Right click this button
- Select "Add to Favorites", click "Continue" if you see a security alert
- In "Create in" menu, select "Links" (IE7) or "Favorites Bar" (IE8, IE9) to install
Drag this button onto Safari Bookmarks bar to install.
- Springer Protocols
- MD Consult
- Lange Series
- National Academy Press
- NCBI Bookshelf
- Thieme Atlases